多西他赛联合奈达铂治疗复发转移性鼻咽癌的临床研究  

Docetaxel combined with nedaplatin in the treatment of recurrent metastatic nasopharyngeal carcinoma

作　　者：黄汉生 杨兰平 

机构地区：[1]广西壮族自治区柳州市肿瘤医院化疗科,广西柳州545006

出　　处：《实用临床医药杂志》2012年第3期87-89,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(41120002)

摘　　要：目的探讨多西他赛联合奈达铂治疗复发和（或）转移性鼻咽癌的临床疗效及不良反应。方法复发和（或）转移性鼻咽癌患者40例,经2个周期以上多西他赛联合奈达铂化疗后,评价临床疗效及不良反应。结果 40例患者均按化疗方案完成化疗,每例患者完成化疗2~4个周期,共完成134个周期化疗。化疗结束时有效率为85.0%,化疗后3个月RR为92.5%。中位无疾病进展时间7.9个月;1年生存率92.5%,中位生存时间18.7个月。不良反应主要以骨髓抑制为主。结论多西他赛联合奈达铂治疗复发和（或）转移性鼻咽癌有效率高,为有效治疗方案。Objective To explore the clinical efficacy and adverse reactions of docetaxel combined with nedaplatin for recurrent metastatic nasopharyngeal carcinoma.Methods Forty patients with recurrent metastatic nasopharyngeal carcinoma were included in the study.The clinical efficacy and adverse reactions were evaluated after they received two-cycle chemotherapy of docetaxel combined with nedaplatin.Results All patients completed chemotherapy.Each patient completed 2 to 4 cycles.A total of 134 cycles of chemotherapy were recorded.At the end of chemotherapy,the efficacy rate was 85.0%,and it was 92.5% three months later.The median time of progression was 7.9 months,1-year survival rate was 92.5%,and the median survival time was 18.7 months.The main adverse events were bone marrow suppressions.Conclusion Docetaxel combined with nedaplatin for recurrent metastatic nasopharyngeal carcinoma is effective.

关 键 词：多西他赛 奈达铂 复发转移性鼻咽癌 

分 类 号：R730.53[医药卫生—肿瘤] R739.63[医药卫生—临床医学]